Publications of Jing Jie Yu, MD

Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
He J, Yu JJ, Xu Q, Wang L, Zheng JZ, Liu LZ, Jiang BH.
Autophagy. 2015;11(2):373-384.


Tungsten carbide-cobalt nanoparticles induce reactive oxygen species, AKT, ERK, AP-1, NF-kappaB, VEGF, and angiogenesis.
Liu LZ, Ding M, Zheng JZ, Zhu Y, Fenderson BA, Li BY, Yu JJ, Jiang BH.
Biol Trace Elem.Res. 2015;166(1):57-65.

PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer.
Ma JX, Yan BX, Zhang J, Jiang BH, Guo Y, Riedel H, Mueller MD, Remick SC, Yu JJ.
Cell Death Dis. 2014;5:e1407

PMC Journal – In Process.

Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin.
Yan BX, Ma JX, Zhang J, Guo Y, Mueller MD, Remick SC, Yu JJ.
Cell Death Dis. 2014;5:e995


PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer.
Yan BX, Ma JX, Zhang J, Guo Y, Riedel H, Mueller MD, Remick SC, Yu JJ.
Oncogene. 2014;33(45):5288-5294.

Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.
Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs GR, Peer CJ, Petros WP.
Cancer Chemother Pharmacol. 2014;73(5):991-997.


Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of Chinese pre-clinical and clinical profile and emerging mechanistic studies.
Yu JJ, Yang X, Song Q, Mueller MD, Remick SC.
Anticancer Res. 2014;34(1):455-463.

Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros WP, Mueller MD, Yu JJ.
Oncol Rep. 2012;27(1):286-292.

The role of Wild-Type p53 in cisplatin-induced Chk2 phosphorylation and the inhibition of platinum resistance with a Chk2 inhibitor.
Liang XB, Guo Y, Figg WD, Fojo AT, Mueller MD, Yu JJ.
Chemother Res Pract. 2011;2011:715469


A polymorphic variant of AFAP-110 enhances cSrc activity.
Clump DA, Yu JJ, Cho Y, Gao R, Jett J, Zot HM, Cunnick JM, Snyder B, Clump AC, Dodrill M, Gannett PM, Coad JE, Shurina R, Figg WD, Reed E, Flynn DC.
Transl Oncol. 2010;3(4):276-285.


HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma.
Yu JJ, Fu PF, Pink JJ, Dawson D, Wasman JK, Orem JN, Mwanda WO, Zhu HL, Liang XB, Guo Y, Petros WP, Mitsuyasu RT, Wabinga H, Remick SC.
PLoS One. 2010;5(5):e10477


Gene expression patterns in the histopathological classification of epithelial ovarian cancer.
Zhu H, Yu JJ.
Exp Ther Med. 2010;1(1):187-192.


EGFR artifactual mutations associated with two DNA sequencers.
Yu JJ, Flynn DC.
Biotechniques. 2007;42(1):41

Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells.
Liang XB, Reed E, Yu JJ.
Int J Mol Med. 2006;17(5):703-708.

MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW, Reed E, Zhong XS, Thornton K, Guo Y, Yu JJ.
Biochem Pharmacol. 2006;71(6):761-771.

Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo.
You Y, Pu P, Huang Q, Xia Z, Wang C, Wang G, Yu C, Yu JJ, Reed E, Li QQ.
Int J Oncol. 2006;28(5):1225-1232.

Excision repair cross complementing-group 1: gene expression and platinum resistance.
Altaha R, Liang XB, Yu JJ, Reed E.
Int J Mol Med. 2004;14(6):959-970.

Confirmation of 42-bp deletion within the ERCC1 5' UTR.
Li TY, Song Y, Liang XB, Guo Y, Reed E, Yu JJ.
Int J Oncol. 2004;25(4):1105-1111.

Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
Yunmbam MK, Guo Y, Miller MR, Yu JJ.
Oncol Rep. 2004;11(4):833-838.

Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer.
Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL.
Clin Cancer Res. 2003;9(14):5299-5305.

Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ, Yunmbam MK, Zhong X, Yu JJ, Mimnaugh EG, Neckers L, Reed E.
Cell Mol Biol (Noisy-le-grand). 2001;47 Online Pub:OL61-OL72.

An ERCC1 splicing variant involving the 5'-UTR of the mRNA may have a transcriptional modulatory function.
Yu JJ, Thornton K, Guo Y, Kotz H, Reed E.
Oncogene. 2001;20(52):7694-7698.

Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells.
Yunmbam MK, Li QQ, Mimnaugh EG, Kayastha GL, Yu JJ, Jones LN, Neckers L, Reed E.
Int J Oncol. 2001;19(4):741-748.

Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.
Dabholkar MD, Thornton K, Vionnet JA, Bostick-Bruton F, Yu JJ, Reed E.
Biochem Pharmacol. 2000;60(11):1611-1619.

Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Li QQ, Yu JJ, Mu CJ, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E.
Anticancer Res. 2000;20(2A):645-652.

Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Reed E, Dabholkar MD, Thornton K, Thompson C, Yu JJ, Bostick-Bruton F.
Oncol Rep. 2000;7(5):1123-1128.

Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
Yu JJ, Bicher A, Ma YK, Bostick-Bruton F, Reed E.
Cancer Lett. 2000;151(2):127-132.

Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ, Lee KB, Mu CJ, Li QQ, Abernathy TV, Bostick-Bruton F, Reed E.
Int J Oncol. 2000;16(3):555-560.

Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.
Li QQ, Ding L, Yu JJ, Mu CJ, Tsang B, Bostick-Bruton F, Reed E.
Int J Oncol. 1998;13(5):987-992.

Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines.
Yu JJ, Mu CJ, Dabholkar MD, Guo Y, Bostick-Bruton F, Reed E.
Int J Mol Med. 1998;1(3):617-620.

A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.
Yu JJ, Mu CJ, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E.
Mutat Res. 1997;382(1-2):13-20.

Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain.
Dabholkar MD, Berger MS, Vionnet JA, Overton L, Thompson C, Bostick-Bruton F, Yu JJ, Silber JR, Reed E.
Mol Carcinog. 1996;17(1):1-7.

Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.
Dabholkar MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ, Reed E.
Cancer Res. 1995;55(6):1261-1266.

The role of physicians in combatting the growing health crisis of tobacco-induced death and disease in the People's Republic of China.
Yu JJ, Glynn TJ, Pechacek TF, Manley MW, Mueller MD, Geng G, Wang S, Gao Y, Lynn WR.
Promot Educ. 1995;2(1):23-30, 58.

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
Dabholkar MD, Vionnet JA, Bostick-Bruton F, Yu JJ, Reed E.
J Clin Invest. 1994;94(2):703-708.


Smoking prevalence and control efforts in China: a brief report from the field.
Yu JJ, Mueller MD.
Hygie. 1990;9(1):22-23.

A comparison of smoking patterns in the People's Republic of China with the United States. An impending health catastrophe in the middle kingdom.
Yu JJ, Mattson ME, Boyd GM, Mueller MD, Shopland DR, Pechacek TF, Cullen JW.
JAMA. 1990;264(12):1575-1579.